Abdel-Raheem Majdi M, Potti Anil, Tadros Sherine, Koka Vijay, Hanekom David, Fraiman Genise, Danielson Byron D
Department of Medicine, University of North Dakota School of Medicine, Fargo, N Dak 58102, USA.
Pathophysiol Haemost Thromb. 2002 May-Jun;32(3):107-10. doi: 10.1159/000065208.
Low-molecular-weight heparins (LMWHs) are being preferred to unfractionated heparin (UFH) because of their superior convenience and a comparable or slightly better toxicity profile. Whether LMWH has an inhibitory effect on aldosterone that causes hyperkalemia is yet uncertain.
Twenty-eight patients (all male; mean age: 70 years, range 52-87 years) placed on LMWH therapy (40 mg subcutaneously every 12 h) for deep venous thrombosis prophylaxis after an operation were included in the study. Transtubular potassium concentration gradient (TTKG) was calculated 1 day prior to LMWH therapy and again after 4 days of treatment. Of the 28 patients enrolled in the study, we were able to calculate the TTKG in only 19 patients: 9 had a urinary osmolarity (either before or after LMWH therapy) less than the serum osmolarity, making the TTKG calculation unreliable. The Wilcoxon signed-rank test was used to analyze differences in the median serum potassium levels and TTKG before and after LMWH therapy.
All patients had adequate renal function (creatinine clearance >90 ml/min). Mean (+/- SD) serum potassium concentration before LMWH was 4.25 (+/- 0.40) mmol/dl. It increased to 4.35 (+/- 0.41) mmol/dl after initiating LMWH therapy (p = 0.09). Similarly, the mean (+/- SD) TKKG calculated was 5.52 (+/- 2.33) before and 5.97 (+/- 3.06) after 4 days of LMWH (p = 0.54).
Unlike UFH, LMWH (Lovenox in doses used for postoperative prophylaxis against deep venous thrombosis does not seem to have a significant effect on potassium homeostasis.
低分子量肝素(LMWHs)因其具有更高的便利性以及相当或略优的毒性特征,正逐渐取代普通肝素(UFH)。低分子量肝素是否对导致高钾血症的醛固酮有抑制作用尚不确定。
本研究纳入了28例患者(均为男性;平均年龄:70岁,范围52 - 87岁),这些患者在手术后接受低分子量肝素治疗(每12小时皮下注射40毫克)以预防深静脉血栓形成。在低分子量肝素治疗前1天以及治疗4天后再次计算跨肾小管钾浓度梯度(TTKG)。在纳入研究的28例患者中,我们仅能对19例患者计算TTKG:9例患者(在低分子量肝素治疗前或治疗后)尿渗透压低于血清渗透压,使得TTKG计算不可靠。采用Wilcoxon符号秩检验分析低分子量肝素治疗前后血清钾水平中位数和TTKG的差异。
所有患者肾功能均正常(肌酐清除率>90毫升/分钟)。低分子量肝素治疗前平均(±标准差)血清钾浓度为4.25(±0.40)毫摩尔/分升。开始低分子量肝素治疗后升至4.35(±0.41)毫摩尔/分升(p = 0.09)。同样,计算所得的平均(±标准差)TTKG在低分子量肝素治疗前为5.52(±2.33),治疗4天后为5.97(±3.06)(p = 0.54)。
与普通肝素不同,低分子量肝素(用于术后预防深静脉血栓形成的剂量的速碧林)似乎对钾稳态没有显著影响。